SI2062573T1 - Proti zlorabi odporni transdermalni sistemi, ki vsebujejo opioid - Google Patents

Proti zlorabi odporni transdermalni sistemi, ki vsebujejo opioid

Info

Publication number
SI2062573T1
SI2062573T1 SI200230970T SI200230970T SI2062573T1 SI 2062573 T1 SI2062573 T1 SI 2062573T1 SI 200230970 T SI200230970 T SI 200230970T SI 200230970 T SI200230970 T SI 200230970T SI 2062573 T1 SI2062573 T1 SI 2062573T1
Authority
SI
Slovenia
Prior art keywords
transdermal systems
abuse resistant
containing transdermal
dosage form
opioid containing
Prior art date
Application number
SI200230970T
Other languages
English (en)
Inventor
Lino Tavares
Bruce E Reidenberg
Richard S Sackler
Curtis Wright
Mark A Alfonso
Benjamin Oshlack
James P Cassidy
Anthony E Carpanzano
Rampurna Prasad Gullapalli
Ihor Shevchuk
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of SI2062573T1 publication Critical patent/SI2062573T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
    • B09B3/00—Destroying solid waste or transforming solid waste into something useful or harmless
    • B09B3/0075—Disposal of medical waste
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
    • B09B2101/00—Type of solid waste
    • B09B2101/65—Medical waste
    • B09B2101/68—Transdermal patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Environmental & Geological Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200230970T 2001-05-01 2002-04-30 Proti zlorabi odporni transdermalni sistemi, ki vsebujejo opioid SI2062573T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28787501P 2001-05-01 2001-05-01
US29253701P 2001-05-22 2001-05-22
EP08020810A EP2062573B1 (en) 2001-05-01 2002-04-30 Abuse resistant opioid containing transdermal systems

Publications (1)

Publication Number Publication Date
SI2062573T1 true SI2062573T1 (sl) 2012-02-29

Family

ID=26964697

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200231061T SI2316439T1 (sl) 2001-05-01 2002-04-30 Proti zlorabi odporni transdermalni sistemi, ki vsebujejo opioid
SI200230785T SI1397095T1 (sl) 2001-05-01 2002-04-30 Pred zlorabo zaščiteni transdermalni sistemi, ki vsebujejo opioid
SI200230970T SI2062573T1 (sl) 2001-05-01 2002-04-30 Proti zlorabi odporni transdermalni sistemi, ki vsebujejo opioid

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI200231061T SI2316439T1 (sl) 2001-05-01 2002-04-30 Proti zlorabi odporni transdermalni sistemi, ki vsebujejo opioid
SI200230785T SI1397095T1 (sl) 2001-05-01 2002-04-30 Pred zlorabo zaščiteni transdermalni sistemi, ki vsebujejo opioid

Country Status (11)

Country Link
US (2) US20040241218A1 (sl)
EP (3) EP2316439B1 (sl)
JP (3) JP5296284B2 (sl)
AT (2) ATE533478T1 (sl)
CY (2) CY1108821T1 (sl)
DE (1) DE60230138D1 (sl)
DK (3) DK2062573T3 (sl)
ES (3) ES2318010T3 (sl)
PT (3) PT2062573E (sl)
SI (3) SI2316439T1 (sl)
WO (1) WO2002087482A1 (sl)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
AU2002339378A1 (en) 2001-05-22 2002-12-03 Euro-Celtique Compartmentalized dosage form
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
KR20050050615A (ko) * 2002-04-23 2005-05-31 알자 코포레이션 남용될 가능성이 감소된 경피용 진통제 시스템
CN101455649B (zh) * 2002-06-10 2014-02-26 欧洲凯尔特公司 防止所含活性剂被误用的经皮给药器的处置系统
EP2422772A3 (en) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
DE10250088A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
CA2522529C (en) * 2003-04-30 2015-10-20 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
CN1829489B (zh) * 2003-07-25 2010-12-15 欧洲凯尔特公司 丁丙诺啡在制备术后疼痛的术前治疗药物中的用途
JP2007527415A (ja) * 2003-10-30 2007-09-27 アルザ・コーポレーシヨン 乱用の可能性が低い経皮鎮痛剤システム
US8535711B2 (en) * 2004-01-23 2013-09-17 Teikoku Pharma Usa, Inc. Medication disposal system
US7867511B2 (en) 2004-01-23 2011-01-11 Travanti Pharma Inc. Abuse potential reduction in abusable substance dosage form
DK2351555T3 (en) * 2004-02-23 2017-01-23 Euro Celtique Sa Abuse-safe transdermal opioid delivery device
KR20070053267A (ko) * 2004-08-20 2007-05-23 쓰리엠 이노베이티브 프로퍼티즈 컴파니 반투명 보호 필름을 갖는 경피 약물 전달 장치
US7226619B1 (en) 2004-09-07 2007-06-05 Pharmorx Inc. Material for controlling diversion of medications
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EP1802258A4 (en) 2004-09-13 2015-09-23 Chrono Therapeutics Inc BIOSYNCHRONE TRANSDERMAL MEDICINES
CN101146523B (zh) * 2004-10-21 2010-12-29 杜雷科特公司 透皮给药系统
WO2006069008A1 (en) * 2004-12-22 2006-06-29 Vesta Medical, Llc Compositions and devices for inactivation of pharmaceuticals to facilitate waste disposal, and methods thereof
US20060182819A1 (en) * 2005-02-17 2006-08-17 Ough Yon D Soap scent patch and treatment for muscle spasm and pain
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
US20060257460A1 (en) * 2005-05-13 2006-11-16 Jansen Rolf R Multilayer drug delivery system with barrier against antagonist exposure
EP1895995A2 (en) 2005-05-13 2008-03-12 Alza Corporation Multilayer drug system for the delivery of galantamine
US20070014839A1 (en) * 2005-07-18 2007-01-18 Stefan Bracht Decomposer film for transdermal patches
EP2308480B1 (en) 2005-09-23 2014-08-13 ALZA Corporation High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications
WO2007035940A2 (en) 2005-09-23 2007-03-29 Alza Corporation Transdermal norelgestromin delivery system
CN101330903B (zh) * 2005-12-13 2015-07-08 生物递送科学国际公司 防滥用的经黏膜给药装置
DE102006025282A1 (de) 2006-05-31 2007-12-20 Lts Lohmann Therapie-Systeme Ag Selbstzerstörendes transdermales therapeutisches System
KR101486228B1 (ko) 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
US20080008747A1 (en) * 2006-07-07 2008-01-10 Royds Robert B Transdermal patch
DK2054031T3 (en) 2006-07-21 2016-05-17 Biodelivery Sciences Int Inc Transmucosal delivery devices with improved uptake
JP2010506833A (ja) * 2006-10-11 2010-03-04 アルファーマ，インコーポレイテッド 医薬組成物
US20080286348A1 (en) * 2007-05-16 2008-11-20 Todhunter John A Secured transdermal delivery system
DE102007041557B4 (de) * 2007-08-29 2011-03-31 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend längliche Hohlkörper
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2009120889A2 (en) * 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
DE102008016804B4 (de) * 2008-04-02 2012-01-05 Lts Lohmann Therapie-Systeme Ag Selbstzerstörendes transdermales therapeutisches System mit verbesserter Funktionalität und Wirksamkeit sowie seine Verwendung
US8481560B2 (en) * 2010-04-02 2013-07-09 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
KR101944367B1 (ko) 2011-08-18 2019-01-31 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 부프레노르핀 운반용 약물남용 억제 점막 부착 장치
CA2846957C (en) 2011-09-30 2017-04-11 Teikoku Pharma Usa, Inc. General medication disposal system
US8790583B2 (en) 2011-09-30 2014-07-29 Teikoku Pharma Usa, Inc. Transdermal patch disposal system
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
CA2962080A1 (en) * 2014-09-24 2016-03-31 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
JP7261586B2 (ja) * 2016-02-26 2023-04-20 ケース ウェスタン リザーブ ユニバーシティ フロー電池用複合膜
JP2020503950A (ja) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 経皮薬剤送達の装置及び方法
US11389844B2 (en) 2018-03-20 2022-07-19 Verde Environmental Technologies, Inc. Blister pack disposal system
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems
WO2020009685A1 (en) * 2018-07-02 2020-01-09 John Tang Transdermal dosage form
WO2020008366A1 (en) * 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal dosage form
EP3870262A1 (en) * 2018-10-23 2021-09-01 Kindeva Drug Delivery L.P. Tamper evident transdermal patch
EP4013390A1 (en) * 2019-08-12 2022-06-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pharmaceutical compositions comprising a combination of opioid antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3643987A1 (de) * 1986-12-22 1988-06-23 Lohmann Therapie Syst Lts Basische, wirkstoffdurchlaessige haftklebende polymermasse, insbesondere zum einsatz mit basischen wirkstoffen, verfahren zu ihrer herstellung und ihre verwendung
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5028435A (en) * 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5573778A (en) * 1995-03-17 1996-11-12 Adhesives Research, Inc. Drug flux enhancer-tolerant pressure sensitive adhesive composition
AU6657396A (en) 1995-07-28 1997-02-26 Novartis Ag Transdermal system
US7011843B2 (en) * 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
EP1041988A4 (en) 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
US6554851B1 (en) * 1999-05-07 2003-04-29 Scimed Life Systems, Inc. Methods of sealing an injection site
EP2266719B1 (en) * 2001-04-23 2016-06-08 Euro-Celtique S.A. Disposal system for transdermal dosage form

Also Published As

Publication number Publication date
ES2546828T3 (es) 2015-09-29
DK1397095T3 (da) 2009-03-09
US20140199383A1 (en) 2014-07-17
EP1397095A1 (en) 2004-03-17
DE60230138D1 (de) 2009-01-15
EP1397095B1 (en) 2008-12-03
ATE533478T1 (de) 2011-12-15
EP2316439B1 (en) 2015-06-17
CY1108821T1 (el) 2014-04-09
JP5296284B2 (ja) 2013-09-25
JP2004529155A (ja) 2004-09-24
JP2013144702A (ja) 2013-07-25
EP2062573B1 (en) 2011-11-16
PT2316439E (pt) 2015-08-28
SI2316439T1 (sl) 2015-10-30
DK2316439T3 (en) 2015-08-10
JP2015042649A (ja) 2015-03-05
EP2316439A1 (en) 2011-05-04
ES2318010T3 (es) 2009-05-01
ES2377672T3 (es) 2012-03-29
CY1112271T1 (el) 2015-12-09
SI1397095T1 (sl) 2009-04-30
EP1397095A4 (en) 2005-05-25
PT2062573E (pt) 2012-01-11
WO2002087482A1 (en) 2002-11-07
EP2062573A1 (en) 2009-05-27
DK2062573T3 (da) 2012-01-30
US20040241218A1 (en) 2004-12-02
ATE415952T1 (de) 2008-12-15
PT1397095E (pt) 2009-02-17

Similar Documents

Publication Publication Date Title
PT2316439E (pt) Sistemas transdérmicos resistentes a violação que contêm opióides
AU2791302A (en) Synergistic medicament containing aromatic agents and having an antagonistic, regenerative and/or protagonist decontamination effect
AU2002227913A1 (en) Synergistic medicament containing aromatic agents and having an antagonistic, regenerative and/or protagonist decontamination effect
EA200600696A1 (ru) Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
DE60127277D1 (de) Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
AU3085102A (en) Drug delivery compositions and medical devices containing block copolymer
AU8659901A (en) Active agent delivery systems and methods for protecting and administering active agents
HUP0300602A3 (en) Diazabicyclic central nervous system active agents, pharmaceutical compositions containing them and their use
EP1392328A4 (en) ANTICANCER THERAPY
MXPA03011825A (es) Combinacion de ingrediente activo para tratar una dependencia de sustancias aditivas o narcoticas utilizando medicamentos.
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
AU5170499A (en) Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
WO2003008637A3 (en) Use of genotyping in the individualization of therapy
EP1064950A4 (en) NEW REMEDIES AGAINST HEPATITIS
DE60110087D1 (de) Verwendung von Carboanhydrase-Inhibitoren zur Prävention von diabetischer Retinopathie bei Diabetikern
DK1156829T3 (da) Stabil formulering indeholdende fumagillin
PL339736A1 (en) Method of protecting persons against contamination due to inadmissible oral taking toxic ingredients of a transdermal therapeutic system and transdermal therapeutic system containing a contaminating agent
SE9803623D0 (sv) New therapeutic application
WO2002026754A3 (de) Oligonukleotide, diese enthaltende mittel und deren verwendung
CY1116853T1 (el) Διαδερμικα συστηματα οπιοειδων περισταλτικα της απροσφορης χρησης
WO2002002089A3 (de) Anthelminthika zur verhinderung von parasitären infektionen bei mensch und tier iv